NovoEight

Country: European Union

Language: Slovenian

Source: EMA (European Medicines Agency)

Buy It Now

Active ingredient:

turoctocog alfa

Available from:

Novo Nordisk A/S

ATC code:

B02BD02

INN (International Name):

turoctocog alfa

Therapeutic group:

koagulacija faktor VIII

Therapeutic area:

Hemofilija A

Therapeutic indications:

Zdravljenje in profilaksa krvavitve pri bolnikih s hemofilijo A (prirojeno pomanjkanje faktorja VIII). Novoeight se lahko uporablja za vse starostne skupine.

Product summary:

Revision: 13

Authorization status:

Pooblaščeni

Authorization date:

2013-11-13

Patient Information leaflet

                                23
9.
POSEBNA NAVODILA ZA SHRANJEVANJE
Shranjujte v hladilniku. Ne zamrzujte.
Zdravilo lahko shranjujete:
•
pri sobni temperaturi (≤ 30 °C) za enkratno obdobje, ki ni daljše
od 9 mesecev,
ALI
•
pri temperaturah, višjih od sobne temperature (30 °C – 40 °C), za
enkratno obdobje, ki ni daljše
od 3 mesecev.
Zdravilo ste vzeli iz hladilnika: ___________ Shranjevanje pri ≤ 30
°C __ Shranjevanje pri 30 °C –
40 °C __
Shranjujte v originalni ovojnini za zagotovitev zaščite pred
svetlobo.
10.
POSEBNI VARNOSTNI UKREPI ZA ODSTRANJEVANJE NEUPORABLJENIH
ZDRAVIL ALI IZ NJIH NASTALIH ODPADNIH SNOVI, KADAR SO POTREBNI
11.
IME IN NASLOV IMETNIKA DOVOLJENJA ZA PROMET Z ZDRAVILOM
Novo Nordisk A/S
Novo Allé
DK-2880 Bagsvaerd
Danska
12.
ŠTEVILKE DOVOLJENJ ZA PROMET
EU/1/13/888/001
13.
ŠTEVILKA SERIJE
_ _
Lot
14.
NAČIN IZDAJANJA ZDRAVILA
_ _
Predpisovanje in izdaja zdravila je le na recept.
15.
NAVODILA ZA UPORABO
16.
PODATKI V BRAILLOVI PISAVI
NovoEight 250 i.e.
17.
EDINSTVENA OZNAKA – DVODIMENZIONALNA ČRTNA KODA_ _
Vsebuje dvodimenzionalno črtno kodo z edinstveno oznako.
24
18.
EDINSTVENA OZNAKA – V BERLJIVI OBLIKI_ _
PC:
SN:
NN:
25
PODATKI, KI MORAJO BITI NAJMANJ NAVEDENI NA MANJŠIH STIČNIH
OVOJNINAH
VIALA
1.
IME ZDRAVILA IN POT UPORABE
NovoEight 250 i.e. prašek za raztopino za injiciranje
turoktokog alfa
za intravensko uporabo
2.
POSTOPEK UPORABE
3.
DATUM IZTEKA ROKA UPORABNOSTI ZDRAVILA
EXP
4.
ŠTEVILKA SERIJE
Lot
5.
VSEBINA, IZRAŽENA Z MASO, PROSTORNINO ALI ŠTEVILOM ENOT
250 i.e.
6.
DRUGI PODATKI
Novo Nordisk A/S
26
PODATKI NA ZUNANJI OVOJNINI
ŠKATLA
1.
IME ZDRAVILA
NovoEight 500 i.e. prašek in vehikel za raztopino za injiciranje
turoktokog alfa (humani koagulacijski faktor VIII (rDNA))
2.
NAVEDBA UČINKOVINE
En mililiter zdravila NovoEight vsebuje po pripravi približno 125
i.e. humanega koagulacijskega
faktorja VIII (rDNA) (turoktokog alfa).
3.
SEZNAM POMOŽNIH SNOVI
Prašek: natrijev klorid, L-histidin, saharoza, polisorbat 80,
L-metionin, kalcijev klorid dihidrat,
natrijev hidroksid in 
                                
                                Read the complete document
                                
                            

Summary of Product characteristics

                                1
PRILOGA I
POVZETEK GLAVNIH ZNAČILNOSTI ZDRAVILA
2
1.
IME ZDRAVILA
NovoEight 250 i.e. prašek in vehikel za raztopino za injiciranje
NovoEight 500 i.e. prašek in vehikel za raztopino za injiciranje
NovoEight 1000 i.e. prašek in vehikel za raztopino za injiciranje
NovoEight 1500 i.e. prašek in vehikel za raztopino za injiciranje
NovoEight 2000 i.e. prašek in vehikel za raztopino za injiciranje
NovoEight 3000 i.e. prašek in vehikel za raztopino za injiciranje
2.
KAKOVOSTNA IN KOLIČINSKA SESTAVA
NovoEight 250 i.e. prašek in vehikel za raztopino za injiciranje
Ena viala s praškom vsebuje nominalno 250 i.e. humanega
koagulacijskega faktorja VIII (rDNA)
(turoktokog alfa).
Po pripravi vsebuje zdravilo NovoEight približno 62,5 i.e./ml
humanega koagulacijskega faktorja VIII
(rDNA) (turoktokog alfa).
NovoEight 500 i.e. prašek in vehikel za raztopino za injiciranje
Ena viala s praškom vsebuje nominalno 500 i.e. humanega
koagulacijskega faktorja VIII (rDNA)
(turoktokog alfa).
Po pripravi vsebuje zdravilo NovoEight približno 125 i.e./ml humanega
koagulacijskega faktorja VIII
(rDNA) (turoktokog alfa).
NovoEight 1000 i.e. prašek in vehikel za raztopino za injiciranje
Ena viala s praškom vsebuje nominalno 1.000 i.e. humanega
koagulacijskega faktorja VIII (rDNA)
(turoktokog alfa).
Po pripravi vsebuje zdravilo NovoEight približno 250 i.e./ml humanega
koagulacijskega faktorja VIII
(rDNA) (turoktokog alfa).
NovoEight 1500 i.e. prašek in vehikel za raztopino za injiciranje
Ena viala s praškom vsebuje nominalno 1.500 i.e. humanega
koagulacijskega faktorja VIII (rDNA)
(turoktokog alfa).
Po pripravi vsebuje zdravilo NovoEight približno 375 i.e./ml humanega
koagulacijskega faktorja VIII
(rDNA) (turoktokog alfa).
NovoEight 2000 i.e. prašek in vehikel za raztopino za injiciranje
Ena viala s praškom vsebuje nominalno 2.000 i.e. humanega
koagulacijskega faktorja VIII (rDNA)
(turoktokog alfa).
Po pripravi vsebuje zdravilo NovoEight približno 500 i.e./ml humanega
koagulacijskega faktorja VIII
(rDNA) (turoktokog alfa).
No
                                
                                Read the complete document
                                
                            

Documents in other languages

Patient Information leaflet Patient Information leaflet Bulgarian 19-05-2021
Summary of Product characteristics Summary of Product characteristics Bulgarian 19-05-2021
Public Assessment Report Public Assessment Report Bulgarian 29-01-2020
Patient Information leaflet Patient Information leaflet Spanish 19-05-2021
Public Assessment Report Public Assessment Report Spanish 29-01-2020
Patient Information leaflet Patient Information leaflet Czech 19-05-2021
Public Assessment Report Public Assessment Report Czech 29-01-2020
Patient Information leaflet Patient Information leaflet Danish 19-05-2021
Public Assessment Report Public Assessment Report Danish 29-01-2020
Patient Information leaflet Patient Information leaflet German 19-05-2021
Public Assessment Report Public Assessment Report German 29-01-2020
Patient Information leaflet Patient Information leaflet Estonian 19-05-2021
Public Assessment Report Public Assessment Report Estonian 29-01-2020
Patient Information leaflet Patient Information leaflet Greek 19-05-2021
Public Assessment Report Public Assessment Report Greek 29-01-2020
Patient Information leaflet Patient Information leaflet English 19-05-2021
Public Assessment Report Public Assessment Report English 29-01-2020
Patient Information leaflet Patient Information leaflet French 19-05-2021
Public Assessment Report Public Assessment Report French 29-01-2020
Patient Information leaflet Patient Information leaflet Italian 19-05-2021
Public Assessment Report Public Assessment Report Italian 29-01-2020
Patient Information leaflet Patient Information leaflet Latvian 19-05-2021
Public Assessment Report Public Assessment Report Latvian 29-01-2020
Patient Information leaflet Patient Information leaflet Lithuanian 19-05-2021
Summary of Product characteristics Summary of Product characteristics Lithuanian 19-05-2021
Public Assessment Report Public Assessment Report Lithuanian 29-01-2020
Patient Information leaflet Patient Information leaflet Hungarian 19-05-2021
Summary of Product characteristics Summary of Product characteristics Hungarian 19-05-2021
Public Assessment Report Public Assessment Report Hungarian 29-01-2020
Patient Information leaflet Patient Information leaflet Maltese 19-05-2021
Public Assessment Report Public Assessment Report Maltese 29-01-2020
Patient Information leaflet Patient Information leaflet Dutch 19-05-2021
Public Assessment Report Public Assessment Report Dutch 29-01-2020
Patient Information leaflet Patient Information leaflet Polish 19-05-2021
Public Assessment Report Public Assessment Report Polish 29-01-2020
Patient Information leaflet Patient Information leaflet Portuguese 19-05-2021
Summary of Product characteristics Summary of Product characteristics Portuguese 19-05-2021
Public Assessment Report Public Assessment Report Portuguese 29-01-2020
Patient Information leaflet Patient Information leaflet Romanian 19-05-2021
Public Assessment Report Public Assessment Report Romanian 29-01-2020
Patient Information leaflet Patient Information leaflet Slovak 19-05-2021
Public Assessment Report Public Assessment Report Slovak 29-01-2020
Patient Information leaflet Patient Information leaflet Finnish 19-05-2021
Public Assessment Report Public Assessment Report Finnish 07-08-2018
Patient Information leaflet Patient Information leaflet Swedish 19-05-2021
Public Assessment Report Public Assessment Report Swedish 29-01-2020
Patient Information leaflet Patient Information leaflet Norwegian 19-05-2021
Summary of Product characteristics Summary of Product characteristics Norwegian 19-05-2021
Patient Information leaflet Patient Information leaflet Icelandic 19-05-2021
Summary of Product characteristics Summary of Product characteristics Icelandic 19-05-2021
Patient Information leaflet Patient Information leaflet Croatian 19-05-2021
Public Assessment Report Public Assessment Report Croatian 29-01-2020

Search alerts related to this product

View documents history